1 Pulmonary Arterial Hypertension (PAH) Medicine Market Overview 1.1 Product Overview and Scope of Pulmonary Arterial Hypertension (PAH) Medicine 1.2 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Calcium Channel Blockers 1.2.3 Novel Targeted Drugs 1.2.4 Other 1.3 Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application 1.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Comparison by Application: (2021-2027) 1.3.2 Secondary Pulmonary Hypertension (SPH) 1.3.3 Primary Pulmonary Hypertension (PPH) 1.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Estimates and Forecasts 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue 2016-2027 1.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales 2016-2027 1.4.3 Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region: 2016 Versus 2021 Versus 2027 2 Pulmonary Arterial Hypertension (PAH) Medicine Market Competition by Manufacturers 2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturers (2016-2021) 2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Sites, Area Served, Product Type 2.5 Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Situation and Trends 2.5.1 Pulmonary Arterial Hypertension (PAH) Medicine Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Pulmonary Arterial Hypertension (PAH) Medicine Players Market Share by Revenue 2.5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Pulmonary Arterial Hypertension (PAH) Medicine Retrospective Market Scenario by Region 3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country 3.3.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country 3.3.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country 3.4.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country 3.4.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Region 3.5.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region 3.5.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 China Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.6 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country 3.6.1 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country 3.6.2 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Facts & Figures by Country 3.7.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country 3.7.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 UAE 4 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Analysis by Type 4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2016-2021) 4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2016-2021) 4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Type (2016-2021) 5 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Analysis by Application 5.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2016-2021) 5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2016-2021) 5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Pfizer 6.1.1 Pfizer Corporation Information 6.1.2 Pfizer Description and Business Overview 6.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio 6.1.5 Pfizer Recent Developments/Updates 6.2 Gilead Sciences 6.2.1 Gilead Sciences Corporation Information 6.2.2 Gilead Sciences Description and Business Overview 6.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio 6.2.5 Gilead Sciences Recent Developments/Updates 6.3 Eli Lilly 6.3.1 Eli Lilly Corporation Information 6.3.2 Eli Lilly Description and Business Overview 6.3.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio 6.3.5 Eli Lilly Recent Developments/Updates 6.4 Actelion Pharmaceuticals 6.4.1 Actelion Pharmaceuticals Corporation Information 6.4.2 Actelion Pharmaceuticals Description and Business Overview 6.4.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio 6.4.5 Actelion Pharmaceuticals Recent Developments/Updates 6.5 United Therapeutics Corporation 6.5.1 United Therapeutics Corporation Corporation Information 6.5.2 United Therapeutics Corporation Description and Business Overview 6.5.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2016-2021) 6.5.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio 6.5.5 United Therapeutics Corporation Recent Developments/Updates 7 Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Cost Analysis 7.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Medicine 7.4 Pulmonary Arterial Hypertension (PAH) Medicine Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors List 8.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers 9 Pulmonary Arterial Hypertension (PAH) Medicine Market Dynamics 9.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends 9.2 Pulmonary Arterial Hypertension (PAH) Medicine Growth Drivers 9.3 Pulmonary Arterial Hypertension (PAH) Medicine Market Challenges 9.4 Pulmonary Arterial Hypertension (PAH) Medicine Market Restraints 10 Global Market Forecast 10.1 Pulmonary Arterial Hypertension (PAH) Medicine Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Medicine by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Medicine by Type (2022-2027) 10.2 Pulmonary Arterial Hypertension (PAH) Medicine Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2022-2027) 10.3 Pulmonary Arterial Hypertension (PAH) Medicine Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Pulmonary Arterial Hypertension (PAH) Medicine by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Pulmonary Arterial Hypertension (PAH) Medicine by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Covered in This Study Table 5. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturers (2016-2021) Table 7. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Pulmonary Arterial Hypertension (PAH) Medicine Average Price (USD/Units) of Key Manufacturers (2016-2021) Table 10. Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Sites and Area Served Table 11. Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Pulmonary Arterial Hypertension (PAH) Medicine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Medicine as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2016-2021) & (K Units) Table 16. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2016-2021) Table 17. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2016-2021) & (K Units) Table 19. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2016-2021) Table 20. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2016-2021) Table 22. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2016-2021) & (K Units) Table 23. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2016-2021) Table 24. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2016-2021) Table 30. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2016-2021) & (K Units) Table 31. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2016-2021) Table 32. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Country (2016-2021) Table 38. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) by Type (2016-2021) Table 39. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2016-2021) Table 40. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (Million US$) by Type (2016-2021) Table 41. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Type (2016-2021) Table 42. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (USD/Units) by Type (2016-2021) Table 43. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units) by Application (2016-2021) Table 44. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2016-2021) Table 45. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (Million US$) by Application (2016-2021) Table 46. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Application (2016-2021) Table 47. Global Pulmonary Arterial Hypertension (PAH) Medicine Price (USD/Units) by Application (2016-2021) Table 48. Pfizer Corporation Information Table 49. Pfizer Description and Business Overview Table 50. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (Million US$), Price (USD/Units) and Gross Margin (2016-2021) Table 51. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Table 52. Pfizer Recent Developments/Updates Table 53. Gilead Sciences Corporation Information Table 54. Gilead Sciences Description and Business Overview Table 55. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (Million US$), Price (USD/Units) and Gross Margin (2016-2021) Table 56. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Table 57. Gilead Sciences Recent Developments/Updates Table 58. Eli Lilly Corporation Information Table 59. Eli Lilly Description and Business Overview Table 60. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (Million US$), Price (USD/Units) and Gross Margin (2016-2021) Table 61. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Table 62. Eli Lilly Recent Developments/Updates Table 63. Actelion Pharmaceuticals Corporation Information Table 64. Actelion Pharmaceuticals Description and Business Overview Table 65. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (Million US$), Price (USD/Units) and Gross Margin (2016-2021) Table 66. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Table 67. Actelion Pharmaceuticals Recent Developments/Updates Table 68. United Therapeutics Corporation Corporation Information Table 69. United Therapeutics Corporation Description and Business Overview Table 70. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Revenue (Million US$), Price (USD/Units) and Gross Margin (2016-2021) Table 71. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Table 72. United Therapeutics Corporation Recent Developments/Updates Table 73. Production Base and Market Concentration Rate of Raw Material Table 74. Key Suppliers of Raw Materials Table 75. Pulmonary Arterial Hypertension (PAH) Medicine Distributors List Table 76. Pulmonary Arterial Hypertension (PAH) Medicine Customers List Table 77. Pulmonary Arterial Hypertension (PAH) Medicine Market Trends Table 78. Pulmonary Arterial Hypertension (PAH) Medicine Growth Drivers Table 79. Pulmonary Arterial Hypertension (PAH) Medicine Market Challenges Table 80. Pulmonary Arterial Hypertension (PAH) Medicine Market Restraints Table 81. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Type (2022-2027) & (K Units) Table 82. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Type (2022-2027) Table 83. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Type (2022-2027) & (US$ Million) Table 84. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share Forecast by Type (2022-2027) Table 85. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Application (2022-2027) & (K Units) Table 86. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Application (2022-2027) Table 87. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Application (2022-2027) & (US$ Million) Table 88. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share Forecast by Application (2022-2027) Table 89. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecast by Region (2022-2027) & (K Units) Table 90. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share Forecast by Region (2022-2027) Table 91. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Forecast by Region (2022-2027) & (US$ Million) Table 92. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share Forecast by Region (2022-2027) Table 93. Research Programs/Design for This Report Table 94. Key Data Information from Secondary Sources Table 95. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Pulmonary Arterial Hypertension (PAH) Medicine Figure 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Type in 2020 & 2027 Figure 3. Calcium Channel Blockers Product Picture Figure 4. Novel Targeted Drugs Product Picture Figure 5. Other Product Picture Figure 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Application in 2020 & 2027 Figure 7. Secondary Pulmonary Hypertension (SPH) Figure 8. Primary Pulmonary Hypertension (PPH) Figure 9. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 10. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size 2016-2027 (US$ Million) Figure 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales 2016-2027 (K Units) Figure 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 13. Pulmonary Arterial Hypertension (PAH) Medicine Sales Share by Manufacturers in 2020 Figure 14. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Manufacturers in 2020 Figure 15. The Global 5 and 10 Largest Pulmonary Arterial Hypertension (PAH) Medicine Players: Market Share by Revenue in 2020 Figure 16. Pulmonary Arterial Hypertension (PAH) Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 17. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2016-2021) Figure 18. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region in 2020 Figure 19. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2016-2021) Figure 20. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region in 2020 Figure 21. U.S. Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 22. Canada Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 23. Germany Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. France Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. U.K. Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Italy Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Russia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. China Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Japan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. South Korea Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. India Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. Australia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. China Taiwan Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Indonesia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Thailand Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Malaysia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Mexico Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Brazil Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Argentina Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Turkey Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. UAE Pulmonary Arterial Hypertension (PAH) Medicine Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Sales Market Share of Pulmonary Arterial Hypertension (PAH) Medicine by Type (2016-2021) Figure 44. Sales Market Share of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2016-2021) Figure 45. Sales Market Share of Pulmonary Arterial Hypertension (PAH) Medicine by Application in 2020 Figure 46. Revenue Share of Pulmonary Arterial Hypertension (PAH) Medicine by Application (2016-2021) Figure 47. Revenue Share of Pulmonary Arterial Hypertension (PAH) Medicine by Application in 2020 Figure 48. Manufacturing Cost Structure of Pulmonary Arterial Hypertension (PAH) Medicine Figure 49. Manufacturing Process Analysis of Pulmonary Arterial Hypertension (PAH) Medicine Figure 50. Pulmonary Arterial Hypertension (PAH) Medicine Industrial Chain Analysis Figure 51. Channels of Distribution Figure 52. Distributors Profiles Figure 53. Bottom-up and Top-down Approaches for This Report Figure 54. Data Triangulation Figure 55. Key Executives Interviewed

Pfizer Gilead Sciences Eli Lilly Actelion Pharmaceuticals United Therapeutics Corporation